У нас вы можете посмотреть бесплатно AROATXN2-1001: A Phase 1 Placebo-controlled Study to Evaluate ARO-ATXN2 in Adult Subjects with SCA2 или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
This webinar provided information about Arrowhead Pharmaceuticals’ ongoing Phase 1 study of ARO-ATXN2 in patients with Spinocerebellar Ataxia Type 2 (SCA2), including the rationale for an siRNA therapeutic approach, an overview of the study design and eligibility requirements for participation, and how patients can contact sites to learn more. Anyone considering participating in a clinical trial or trying a new medication should discuss the matter with their physician. NAF does not endorse or recommend any particular studies or treatment options. For more information on Ataxia, please visit our website: https://www.ataxia.org Become a Free NAF member! https://bit.ly/JoinNAF Follow us on Social Media! NAF Facebook: / ataxiafounda. . NAF Twitter: / naf_ataxia NAF Instagram: / ataxiafound. . Ataxia Subreddit: / ataxia About the Speaker: Speaker: Sharan Srinivasan, MD, PhD Institution: University of Michigan Bio: Dr. Sharan Srinivasan is an Assistant Professor within the Movement Disorders Division in the Department of Neurology at the University of Michigan. He attended Northwestern University for his bachelor's degree and obtained his combined M.D. Ph.D. at the University of Michigan. He then completed his residency in Neurology at the University of Michigan before pursuing a movement disorders fellowship at Mass General Brigham (Harvard). He returned to the University of Michigan in 2022 to continue his clinical and scientific efforts in caring for and treating cerebellar ataxias. Clinically, Dr. Srinivasan co-directs the UM Ataxia Center of Excellence and is UM site PI for the Clinical Research Consortium for the Study of Cerebellar Ataxias. His research interests involve the pathophysiology of cerebellar ataxias, particularly hereditary polyglutamine disorders. His passion is in developing novel therapeutics via a multidisciplinary approach, combining strategies from organic chemistry, molecular biology, neuro-circuitry, and emerging genetic technologies. His focus has been on targeting impaired neuronal circuitry within these disorders, the amelioration of which has been shown to improve motor symptoms and delay degeneration. Speaker: Massimo Pandolfo, MD Institution: McGill University Bio: Massimo Pandolfo, MD, is Professor of Neurology at McGill University and Medical Director of the Clinical Research Unit at the Montreal Neurological Institute. He earned his medical degree and completed his neurology residency at the University of Milan, followed by academic appointments at Baylor College of Medicine, Université de Montréal, and Université Libre de Bruxelles, where he also served as Chief of the Neurology Service. A Fellow of both the American Academy of Neurology and the European Academy of Neurology, Dr. Pandolfo is internationally recognized for his work on ataxias. In 1996, he led the team that discovered the gene responsible for Friedreich ataxia, a breakthrough that shaped the field. Since then, he has remained at the forefront of basic, translational, and clinical research on Friedreich ataxia and other hereditary ataxias. Dr. Pandolfo leads multi-investigator translational initiatives and serves as principal investigator in several clinical trials. His current work focuses on advancing innovative therapies for neurodegenerative diseases, with a particular emphasis on clinical trial design and the development of advanced neurotherapeutics. Speaker: Greg Shekhtman, MD Institution: Arrowhead Pharmaceuticals Bio: Greg Shekhtman is the Medical Monitor for the AROATXN2-1001 study and a Medical Director with Arrowhead Pharmaceuticals. He obtained his medical degree from the University of California, Los Angeles, and completed both his residency in Internal Medicine and fellowship in Nephrology at the Ronald Reagan Medical Center at UCLA.